• News
  • SAN DIEGO
  • Finance

Allergan board turns down Valeant takeover offer

Botox maker Allergan is rejecting a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited bid worth nearly $46 billion undervalues the company and carries significant risk.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!